Genuine Biotech takes third shot at IPO as financial pressures mount
对赌协议压顶之下 真实生物三闯港交所

Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma.
核心产品阿兹夫定市场需求早已消退，与复星医药合作终止导致营收断崖式下滑，现金流濒临枯竭，还有一份仅剩7个月期限的上市对赌协议。